Focus on HIV Care

Back to articles

Nucleoside reverse transcriptase inhibitors linked to increased risk of MI


An observational analysis of the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study revealed that patients recently exposed to abacavir (Ziagen—GlaxoSmithKline) or didanosine therapy were at an increased risk of myocardial infarction (MI); however, no association was seen in patients exposed to zidovudine, stavudine (Zerit—Bristol-Myers Squibb), or lamivudine (Epivir—GlaxoSmithKline).


D:A:D Study group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multicohort collaboration. Lancet. 2008;371:1417–26. 

Stein JH et al. Risk of myocardial infarction and nucleoside analogues [comment]. Lancet. 2008;371:1391–2. 

Cutrell A et al. Abacavir and the potential risk of myocardial infarction [correspondence]. Lancet. 2008;371:1413.